The epigenome as a molecular marker and target: Implications for cancer

Cancer

Volumn 104, Issue 9, 2005, Pages 1789-1793

  Gius, David ^a   Bradbury, C Matthew ^a   Sun, Lunching ^a   Awwad, Rania T ^a   Huang, Lei ^a   Smart, Dee Dee K ^a   Bisht, Kheem S ^a   Ho, Alien S ^a   Nguyen, Phuongmai ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DNMT; Epigenome; Methylation; Molecular marker

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 1 INHIBITOR; GROWTH FACTOR; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; MOLECULAR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER GENETICS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DNA METHYLATION; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW;

AZACITIDINE; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 27244442597     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21395     Document Type: Review

References (21)

1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
2. Chung JH, Whiteley M, Felsenfeld G. A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell. 1993;74:505-514.
3. Feinberg AP, Cui H, Ohlsson R. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol. 2002;12:389-398.
4. Gregory PD. Transcription and chromatin converge: lessons from yeast genetics. Curr Opin Genet Dev. 2001;11:142-147.
5. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89-92.
6. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489-492.
7. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-153.
8. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989;83:155-158.
9. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991;48:880-888.
10. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene. 1993;8:1063-1067.
11. Gius D, Hengmi C, Bradbury MC, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004;6:361-371.
12. Smart DK, Ortiz KL, Mattson D, et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res. 2004;64:6716-6724.
13. Kaneuchi M, Sasaki M, Tanaka Y, et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer. This issue.
14. Hoque MO, Rosenbaum E, Westra WH, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005;90:4011-4018.
15. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer. 2005;116:407-414.
16. McKie AB, Douglas DA, Olijslagers S, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24:2166-2174.
17. An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005;11:656-663.
18. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or DNMT1. Oncogene. 2004;23:3737-3748.
19. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552-556.
20. Bakin AV, Curran T. Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science. 1999;283:387-390.
21. Laird PW. Cancer epigenetics. Hum. Mol. Genet. 2005; 14:R65-R76.